Barclays’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-23,200
| Closed | -$1.38M | – | 5066 |
|
|
2025
Q4 | $1.38M | Buy |
+23,200
| New | +$1.26M | ﹤0.01% | 3207 |
|
|
2025
Q2 | – | Sell |
-28,800
| Closed | -$2.04M | – | 5271 |
|
|
2025
Q1 | $2.04M | Buy |
28,800
+2,300
| +9% | +$155K | ﹤0.01% | 2619 |
|
|
2024
Q4 | $1.74M | Sell |
26,500
-9,400
| -26% | -$630K | ﹤0.01% | 2985 |
|
|
2024
Q3 | $2.52M | Buy |
+35,900
| New | +$3M | ﹤0.01% | 2662 |
|
|
2024
Q2 | – | Sell |
-50,400
| Closed | -$4.4M | – | 4896 |
|
|
2024
Q1 | $4.4M | Buy |
50,400
+1,000
| +2% | +$89.5K | ﹤0.01% | 1956 |
|
|
2023
Q4 | $4.76M | Buy |
+49,400
| New | +$4.37M | ﹤0.01% | 2138 |
|
|
2022
Q1 | – | Sell |
-197,000
| Closed | -$17.4M | – | 4975 |
|
|
2021
Q4 | $17.4M | Buy |
+197,000
| New | +$16.3M | 0.01% | 1001 |
|
|
2021
Q3 | – | Sell |
-42,400
| Closed | -$3.54M | – | 4752 |
|
|
2021
Q2 | $3.54M | Buy |
+42,400
| New | +$3.36M | ﹤0.01% | 1803 |
|
|
2021
Q1 | – | Sell |
-160,000
| Closed | -$14M | – | 4708 |
|
|
2020
Q4 | $14M | Buy |
+160,000
| New | +$12.7M | 0.01% | 1009 |
|
|
2020
Q3 | – | Sell |
-36,300
| Closed | -$4.48M | – | 5228 |
|
|
2020
Q2 | $4.48M | Buy |
36,300
+15,900
| +78% | +$1.58M | ﹤0.01% | 1468 |
|
|
2020
Q1 | $1.72M | Sell |
20,400
-16,300
| -44% | -$1.4M | ﹤0.01% | 2420 |
|
|
2019
Q4 | $3.1M | Sell |
36,700
-27,200
| -43% | -$2.05M | ﹤0.01% | 2537 |
|
|
2019
Q3 | $4.31M | Sell |
63,900
-115,900
| -64% | -$8.93M | ﹤0.01% | 1991 |
|
|
2019
Q2 | $15.4M | Sell |
179,800
-53,000
| -23% | -$4.53M | 0.01% | 1084 |
|
|
2019
Q1 | $20.7M | Buy |
232,800
+139,900
| +151% | +$13M | 0.01% | 838 |
|
|
2018
Q4 | $7.91M | Sell |
92,900
-38,800
| -29% | -$3.69M | 0.01% | 1296 |
|
|
2018
Q3 | $12.8M | Sell |
131,700
-42,200
| -24% | -$4.21M | 0.01% | 1116 |
|
|
2018
Q2 | $16.4M | Buy |
173,900
+106,000
| +156% | +$9.28M | 0.01% | 890 |
|
|
2018
Q1 | $5.5M | Sell |
67,900
-66,800
| -50% | -$5.73M | ﹤0.01% | 1567 |
|
|
2017
Q4 | $12M | Buy |
134,700
+27,400
| +26% | +$2.38M | 0.01% | 1089 |
|
|
2017
Q3 | $9.99M | Buy |
107,300
+56,400
| +111% | +$4.98M | 0.01% | 1056 |
|
|
2017
Q2 | $4.62M | Buy |
50,900
+18,100
| +55% | +$1.65M | 0.01% | 1530 |
|
|
2017
Q1 | $2.88M | Sell |
32,800
-9,300
| -22% | -$827K | ﹤0.01% | 1746 |
|
|
2016
Q4 | $3.49M | Sell |
42,100
-9,500
| -18% | -$817K | ﹤0.01% | 1649 |
|
|
2016
Q3 | $4.77M | Buy |
51,600
+27,300
| +112% | +$2.57M | 0.01% | 1334 |
|
|
2016
Q2 | $1.89M | Buy |
24,300
+5,400
| +29% | +$459K | ﹤0.01% | 2054 |
|
|
2016
Q1 | $1.55M | Sell |
18,900
-357,200
| -95% | -$29.1M | ﹤0.01% | 2151 |
|
|
2015
Q4 | $39.1M | Sell |
376,100
-26,400
| -7% | -$2.76M | 0.05% | 352 |
|
|
2015
Q3 | $42.3M | Buy |
402,500
+140,800
| +54% | +$18.8M | 0.05% | 321 |
|
|
2015
Q2 | $35.6M | Buy |
261,700
+145,400
| +125% | +$18M | 0.04% | 411 |
|
|
2015
Q1 | $14.4M | Buy |
116,300
+39,300
| +51% | +$4.16M | 0.02% | 865 |
|
|
2014
Q4 | $6.93M | Buy |
77,000
+49,400
| +179% | +$4.11M | 0.01% | 1440 |
|
|
2014
Q3 | $1.99M | Sell |
27,600
-456,100
| -94% | -$30M | ﹤0.01% | 2670 |
|
|
2014
Q2 | $30M | Sell |
483,700
-371,700
| -43% | -$22.5M | 0.03% | 499 |
|
|
2014
Q1 | $58.2M | Buy |
855,400
+641,300
| +300% | +$47.3M | 0.07% | 257 |
|
|
2013
Q4 | $15M | Buy |
214,100
+179,900
| +526% | +$12.2M | 0.02% | 961 |
|
|
2013
Q3 | $2.46M | Sell |
34,200
-197,200
| -85% | -$13.1M | ﹤0.01% | 2348 |
|
|
2013
Q2 | $12.9M | Buy |
+231,400
| New | +$14.4M | 0.02% | 894 |
|
Other funds holding BMRN
VCM
VPM
Barclays's BMRN Position: Q1 2026 in Review
Barclays reduced its BioMarin Pharmaceuticals (BMRN) stake by 57% in Q1 2026, selling an estimated $9.66M and leaving 122,838 shares worth $6.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1634.
Barclays first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $510M in Q4 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Barclays held 122,838 shares of BioMarin Pharmaceuticals worth $6.94M as of Q1 2026.
- Barclays sold 165,709 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $9.66M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1634 holding.
- Barclays first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's BioMarin Pharmaceuticals position peaked at $510M in Q4 2023.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.